MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q3
hinzugefügt 02.11.2023
ImmunoGen Anteile 2011-2025 | IMGN
Anteile Jährlich ImmunoGen
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 254 M | 206 M | 176 M | 148 M | 140 M | 98.1 M | 87 M | 86 M | 85.5 M | 84.1 M | 76.8 M | 68.9 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 254 M | 68.9 M | 126 M |
Anteile Vierteljährlich ImmunoGen
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 273 M | 263 M | 259 M | 226 M | 254 M | 253 M | 253 M | 220 M | 205 M | 200 M | 199 M | 195 M | 175 M | 174 M | 167 M | 150 M | 148 M | 148 M | 148 M | 149 M | 147 M | 134 M | 131 M | 133 M | 93 M | 87.2 M | 87.2 M | 87.3 M | 87.1 M | 87.1 M | 87 M | 87 M | 86 M | 86.9 M | 86.1 M | 85.9 M | 85.9 M | 85.9 M | 85.9 M | 85.4 M | 85 M | 85.4 M | 85 M | 84.1 M | 83.4 M | 83.7 M | 77 M | 76.5 M | 76.4 M | 76.4 M | 68.1 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 273 M | 68.1 M | 135 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
166 M | $ 4.93 | 4.78 % | $ 818 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
77.3 M | $ 3.2 | -1.69 % | $ 247 M |  USA |
 |
AlloVir
ALVR
|
5.01 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
276 K | $ 1.07 | -5.75 % | $ 295 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
54.8 M | $ 213.33 | -3.22 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
2.41 B | $ 3.13 | -4.96 % | $ 7.53 B |  Australia |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
BioVie
BIVI
|
1.48 M | $ 1.42 | -1.85 % | $ 2.1 M | USA |
 |
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.21 B | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
244 M | $ 93.93 | -0.93 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
60.3 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
48.4 M | $ 26.45 | 4.67 % | $ 1.28 B | USA |
 |
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
14.7 M | $ 9.6 | 0.37 % | $ 141 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.18 B | $ 0.26 | -6.98 % | $ 566 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
65.8 M | $ 12.98 | -7.91 % | $ 854 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
60.8 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
224 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
44.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
75.7 M | $ 548.58 | -2.78 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
6.28 M | $ 2.37 | 2.83 % | $ 14.9 M | USA |
 |
AstraZeneca PLC
AZN
|
1.42 B | $ 91.59 | 1.95 % | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
64.4 K | $ 27.09 | -1.53 % | $ 1.74 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
5.39 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
219 M | $ 8.97 | -0.44 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
1.37 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
64.7 M | $ 11.33 | -1.78 % | $ 733 M | USA |
 |
Biogen
BIIB
|
146 M | $ 175.2 | 0.63 % | $ 25.5 B | USA |
 |
Abeona Therapeutics
ABEO
|
21.4 M | $ 5.07 | -5.5 % | $ 108 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
103 M | $ 87.67 | -0.36 % | $ 9.05 B | USA |
 |
ADiTx Therapeutics
ADTX
|
13.2 K | $ 1.43 | -36.18 % | $ 18.8 K | USA |
 |
Cellectar Biosciences
CLRB
|
12.2 M | $ 3.28 | -9.39 % | $ 40.1 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
30.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
68.9 M | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
118 M | $ 24.29 | 2.84 % | $ 2.88 B | USA |